Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that its Annual Report and Accounts for the period ended 31 December 2019 and the Notice of

Avacta Group announced that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has entered into an exclusive distribution agreement with Medusa19 Limited for direct-to-consumer sales of

Lateral flow assay (LFA) based diagnostic tests are widely used for point of care (POC) and consumer/self-testing, due to the combination of rapid results with cost-effective testing, achievable by non-specialists.

Avacta Group PLC (LON:AVCT) is leveraging the antibody-like properties of Affimers for Therapeutic and Diagnostic applications across multi-billion dollar markets, including testing and treatment for COVID-19, building a differentiated pipeline

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, today announced that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also

Developing the next generation of biotherapeutics Affimer® technology is a novel class of biotherapeutic based on a naturally occurring human protein called Stefin A. Avacta is building a pipeline of clinically

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that today it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners. The Group